Swedish Real World COPD Pneumonia Analysis Backs Symbicort Over Seretide
This article was originally published in The Pink Sheet Daily
Executive Summary
COPD stalwarts Symbicort and Seretide never have been compared head-to-head in the clinic but Swedish researchers now have analyzed the pair’s respective association with pneumonia, using Sweden’s modern infrastructure and national databases. The review concluded that the AstraZeneca compound soundly beats GlaxoSmithKline’s, based on real-world evidence.